Wikipedia

Targeted temperature management

(Redirected from Therapeutic hypothermia)
This article is about deliberately induced cooling. For the adverse condition of hypothermia, see Hypothermia.

Targeted temperature management (TTM) previously known as therapeutic hypothermia or protective hypothermia is an active treatment that tries to achieve and maintain a specific body temperature in a person for a specific duration of time in an effort to improve health outcomes during recovery after a period of stopped blood flow to the brain.[1] This is done in an attempt to reduce the risk of tissue injury following lack of blood flow.[2] Periods of poor blood flow may be due to cardiac arrest or the blockage of an artery by a clot as in the case of a stroke.[3]

Targeted temperature management
Other namesTherapeutic hypothermia
ICD-10-PCS6A4
MeSHC18.452.394.750
OPS-301 code8-607

Targeted temperature management improves survival and brain function following resuscitation from cardiac arrest.[4] Evidence supports its use following certain types of cardiac arrest in which an individual does not regain consciousness.[1] The target temperature is often between 32 and 34 °C.[4] Targeted temperature management following traumatic brain injury is of unclear benefit.[5] While associated with some complications, these are generally mild.[6]

Targeted temperature management is thought to prevent brain injury by several methods, including decreasing the brain's oxygen demand, reducing the production of neurotransmitters like glutamate, as well as reducing free radicals that might damage the brain. Body temperature may be lowered by many means, including cooling blankets, cooling helmets, cooling catheters, ice packs and ice water lavage.

Medical uses

edit

Targeted temperature management may be used in the following conditions:

Cardiac arrest

edit

The 2013 ILCOR and 2010 American Heart Association guidelines support the use of cooling following resuscitation from cardiac arrest.[1][7] These recommendations were largely based on two trials from 2002 which showed improved survival and brain function when cooled to 32–34 °C (90–93 °F) after cardiac arrest.[2][8]

However, more recent research suggests that there is no benefit to cooling to 33 °C (91 °F) when compared with less aggressive cooling only to a near-normal temperature of 36 °C (97 °F); it appears cooling is effective because it prevents fever, a common complication seen after cardiac arrest.[9] There is no difference in long term quality of life following mild compared to more severe cooling.[10]

In children, following cardiac arrest, cooling does not appear useful as of 2018.[11]

A recent Cochrane Review summarized available evidence on the topic and found that targeted temperature management around 33 °C may increase the chance to prevent brain damage after cardiac arrest by 40%.[12]

Neonatal encephalopathy

edit

Hypothermia therapy for neonatal encephalopathy has been proven to improve outcomes for newborn infants affected by perinatal hypoxia-ischemia, hypoxic ischemic encephalopathy or birth asphyxia. A 2013 Cochrane review found that it is useful in full term babies with encephalopathy.[13] Whole body or selective head cooling to 33–34 °C (91–93 °F), begun within six hours of birth and continued for 72 hours, reduces mortality and reduces cerebral palsy and neurological deficits in survivors.[citation needed]

Open heart surgery

edit

Targeted temperature management is used during open-heart surgery because it decreases the metabolic needs of the brain, heart, and other organs, reducing the risk of damage to them. The patient is given medication to prevent shivering. The body is then cooled to 25–32 °C (77–90 °F). The heart is stopped and an external heart-lung pump maintains circulation to the patient's body. The heart is cooled further and is maintained at a temperature below 15 °C (59 °F) for the duration of the surgery. This very cold temperature helps the heart muscle to tolerate its lack of blood supply during the surgery.[14][15]

Adverse effects

edit

Possible complications may include: infection, bleeding, dysrhythmias and high blood sugar.[16] One review found an increased risk of pneumonia and sepsis but not the overall risk of infection.[17] Another review found a trend towards increased bleeding but no increase in severe bleeding.[18] Hypothermia induces a "cold diuresis" which can lead to electrolyte abnormalities – specifically hypokalemia, hypomagnesaemia, and hypophosphatemia, as well as hypovolemia.[19]

Mechanism

edit

The earliest rationale for the effects of hypothermia as a neuroprotectant focused on the slowing of cellular metabolism resulting from a drop in body temperature. For every one degree Celsius drop in body temperature, cellular metabolism slows by 5–7%.[20] Accordingly, most early hypotheses suggested that hypothermia reduces the harmful effects of ischemia by decreasing the body's need for oxygen.[21] The initial emphasis on cellular metabolism explains why the early studies almost exclusively focused on the application of deep hypothermia, as these researchers believed that the therapeutic effects of hypothermia correlated directly with the extent of temperature decline.[22]

In the special case of infants with perinatal asphyxia, it appears that apoptosis is a prominent cause of cell death and that hypothermia therapy for neonatal encephalopathy interrupts the apoptotic pathway. In general, cell death is not directly caused by oxygen deprivation, but occurs indirectly as a result of the cascade of subsequent events. Cells need oxygen to create ATP, a molecule used by cells to store energy, and cells need ATP to regulate intracellular ion levels. ATP is used to fuel both the importation of ions necessary for cellular function and the removal of ions that are harmful to cellular function. Without oxygen, cells cannot manufacture the necessary ATP to regulate ion levels and thus cannot prevent the intracellular environment from approaching the ion concentration of the outside environment. It is not oxygen deprivation itself that precipitates cell death, but rather without oxygen the cell can not make the ATP it needs to regulate ion concentrations and maintain homeostasis.[21]

Notably, even a small drop in temperature encourages cell membrane stability during periods of oxygen deprivation. For this reason, a drop in body temperature helps prevent an influx of unwanted ions during an ischemic insult. By making the cell membrane more impermeable, hypothermia helps prevent the cascade of reactions set off by oxygen deprivation. Even moderate dips in temperature strengthen the cellular membrane, helping to minimize any disruption to the cellular environment. It is by moderating the disruption of homeostasis caused by a blockage of blood flow that many now postulate, results in hypothermia's ability to minimize the trauma resultant from ischemic injuries.[21]

Targeted temperature management may also help to reduce reperfusion injury, damage caused by oxidative stress when the blood supply is restored to a tissue after a period of ischemia. Various inflammatory immune responses occur during reperfusion. These inflammatory responses cause increased intracranial pressure, which leads to cell injury and in some situations, cell death. Hypothermia has been shown to help moderate intracranial pressure and therefore to minimize the harmful effects of a patient's inflammatory immune responses during reperfusion. The oxidation that occurs during reperfusion also increases free radical production. Since hypothermia reduces both intracranial pressure and free radical production, this might be yet another mechanism of action for hypothermia's therapeutic effect.[21] Overt activation of N-methyl-D-aspartate (NMDA) receptors following brain injuries can lead to calcium entry which triggers neuronal death via the mechanisms of excitotoxicity.[23]

Methods

edit

There are a number of methods through which hypothermia is induced.[16] These include: cooling catheters, cooling blankets, and application of ice applied around the body among others.[16][24] As of 2013 it is unclear if one method is any better than the others.[24] While cool intravenous fluid may be given to start the process, further methods are required to keep the person cold.[16]

Core body temperature must be measured (either via the esophagus, rectum, bladder in those who are producing urine, or within the pulmonary artery) to guide cooling.[16] A temperature below 30 °C (86 °F) should be avoided, as adverse events increase significantly.[24] The person should be kept at the goal temperature plus or minus half a degree Celsius for 24 hours.[24] Rewarming should be done slowly with suggested speeds of 0.1 to 0.5 °C (0.18 to 0.90 °F) per hour.[24]

Targeted temperature management should be started as soon as possible.[25] The goal temperature should be reached before 8 hours.[24] Targeted temperature management remains partially effective even when initiated as long as 6 hours after collapse.[26]

Prior to the induction of targeted temperature management, pharmacological agents to control shivering must be administered. When body temperature drops below a certain threshold—typically around 36 °C (97 °F)—people may begin to shiver.[27] It appears that regardless of the technique used to induce hypothermia, people begin to shiver when temperature drops below this threshold.[27] Drugs commonly used to prevent and treat shivering in targeted temperature management include acetaminophen, buspirone, opioids including pethidine (meperidine), dexmedetomidine, fentanyl, and/or propofol.[28] If shivering is unable to be controlled with these drugs, patients are often placed under general anesthesia and/or are given paralytic medication like vecuronium. People should be rewarmed slowly and steadily in order to avoid harmful spikes in intracranial pressure.[26]

Cooling catheters

edit

Cooling catheters are inserted into a femoral vein. Cooled saline solution is circulated through either a metal coated tube or a balloon in the catheter. The saline cools the person's whole body by lowering the temperature of a person's blood. Catheters reduce temperature at rates ranging from 1.5 to 2 °C (2.7 to 3.6 °F) per hour. Through the use of the control unit, catheters can bring body temperature to within 0.1 °C (0.18 °F) of the target level. Furthermore, catheters can raise temperature at a steady rate, which helps to avoid harmful rises in intracranial pressure. A number of studies have demonstrated that targeted temperature management via catheter is safe and effective.[29][30][31][32][33]

Adverse events associated with this invasive technique include bleeding, infection, vascular puncture, and deep vein thrombosis (DVT).[34] Infection caused by cooling catheters is particularly harmful, as resuscitated people are highly vulnerable to the complications associated with infections.[35] Bleeding represents a significant danger, due to a decreased clotting threshold caused by hypothermia. The risk of deep vein thrombosis may be the most pressing medical complication.[citation needed]

Deep vein thrombosis can be characterized as a medical event whereby a blood clot forms in a deep vein, usually the femoral vein. This condition may become potentially fatal if the clot travels to the lungs and causes a pulmonary embolism. Another potential problem with cooling catheters is the potential to block access to the femoral vein, which is a site normally used for a variety of other medical procedures, including angiography of the venous system and the right side of the heart. However, most cooling catheters are triple lumen catheters, and the majority of people post-arrest will require central venous access. Unlike non-invasive methods which can be administered by nurses, the insertion of cooling catheters must be performed by a physician fully trained and familiar with the procedure. The time delay between identifying a person who might benefit from the procedure and the arrival of an interventional radiologist or other physician to perform the insertion may minimize some of the benefit of invasive methods' more rapid cooling.[citation needed]

Transnasal evaporative cooling

edit

Transnasal evaporative cooling is a method of inducing the hypothermia process and provides a means of continuous cooling of a person throughout the early stages of targeted temperature management and during movement throughout the hospital environment. This technique uses two cannulae, inserted into a person's nasal cavity, to deliver a spray of coolant mist that evaporates directly underneath the brain and base of the skull. As blood passes through the cooling area, it reduces the temperature throughout the rest of the body.[citation needed]

The method is compact enough to be used at the point of cardiac arrest, during ambulance transport, or within the hospital proper. It is intended to reduce rapidly the person's temperature to below 34 °C (93 °F) while targeting the brain as the first area of cooling. Research into the device has shown cooling rates of 2.6 °C (4.7 °F) per hour in the brain (measured through infrared tympanic measurement) and 1.6 °C (2.9 °F) per hour for core body temperature reduction.[36][37]

Water blankets

edit

With these technologies, cold water circulates through a blanket, or torso wraparound vest and leg wraps. To lower temperature with optimal speed, 70% of a person's surface area should be covered with water blankets. The treatment represents the most well studied means of controlling body temperature. Water blankets lower a person's temperature exclusively by cooling a person's skin and accordingly require no invasive procedures.[citation needed]

Water blankets possess several undesirable qualities. They are susceptible to leaking, which may represent an electrical hazard since they are operated in close proximity to electrically powered medical equipment.[38] The Food and Drug Administration also has reported several cases of external cooling blankets causing significant burns to the skin of person. Other problems with external cooling include overshoot of temperature (20% of people will have overshoot), slower induction time versus internal cooling, increased compensatory response, decreased patient access, and discontinuation of cooling for invasive procedures such as the cardiac catheterization.[39]

If therapy with water blankets is given along with two litres of cold intravenous saline, people can be cooled to 33 °C (91 °F) in 65 minutes.[citation needed] Most machines now come with core temperature probes. When inserted into the rectum, the core body temperature is monitored and feedback to the machine allows changes in the water blanket to achieve the desired set temperature. In the past some of the models of cooling machines have produced an overshoot in the target temperature and cooled people to levels below 32 °C (90 °F), resulting in increased adverse events. They have also rewarmed patients at too fast a rate, leading to spikes in intracranial pressure. Some of the new models have more software that attempt to prevent this overshoot by utilizing warmer water when the target temperature is close and preventing any overshoot.[citation needed] Some of the new machines now also have 3 rates of cooling and warming; a rewarming rate with one of these machines allows a patient to be rewarmed at a very slow rate of just 0.17 °C (0.31 °F) an hour in the "automatic mode", allowing rewarming from 33 °C (91 °F) to 37 °C (99 °F) over 24 hours.[citation needed]

Cool caps

edit

There are a number of non-invasive head cooling caps and helmets designed to target cooling at the brain.[40] A hypothermia cap is typically made of a synthetic material such as neoprene, silicone, or polyurethane and filled with a cooling agent such as ice or gel which is either cooled to a very cold temperature, −25 to −30 °C (−13 to −22 °F), before application or continuously cooled by an auxiliary control unit. Their most notable uses are in preventing or reducing alopecia in chemotherapy,[41] and for preventing cerebral palsy in babies born with hypoxic ischemic encephalopathy.[42] In the continuously cooled iteration, coolant is cooled with the aid of a compressor and pumped through the cooling cap. Circulation is regulated by means of valves and temperature sensors in the cap. If the temperature deviates or if other errors are detected, an alarm system is activated. The frozen iteration involves continuous application of caps filled with Crylon gel cooled to −30 °C (−22 °F) to the scalp before, during and after intravenous chemotherapy. As the caps warm on the head, multiple cooled caps must be kept on hand and applied every 20 to 30 minutes.

History

edit

Hypothermia has been applied therapeutically since antiquity. The Greek physician Hippocrates, the namesake of the Hippocratic Oath, advocated the packing of wounded soldiers in snow and ice.[21] Napoleonic surgeon Baron Dominique Jean Larrey recorded that officers who were kept closer to the fire survived less often than the minimally pampered infantrymen.[21] In modern times, the first medical article concerning hypothermia was published in 1945.[21] This study focused on the effects of hypothermia on patients with severe head injury. In the 1950s, hypothermia received its first medical application, being used in intracerebral aneurysm surgery to create a bloodless field.[21] Most of the early research focused on the applications of deep hypothermia, defined as a body temperature of 20–25 °C (68–77 °F). Such an extreme drop in body temperature brings with it a whole host of side effects, which made the use of deep hypothermia impractical in most clinical situations.

This period also saw sporadic investigation of more mild forms of hypothermia, with mild hypothermia being defined as a body temperature of 32–34 °C (90–93 °F). In the 1950s, Doctor Rosomoff demonstrated in dogs the positive effects of mild hypothermia after brain ischemia and traumatic brain injury.[21] In the 1980s further animal studies indicated the ability of mild hypothermia to act as a general neuroprotectant following a blockage of blood flow to the brain. This animal data was supported by two landmark human studies that were published simultaneously in 2002 by the New England Journal of Medicine.[43] Both studies, one occurring in Europe and the other in Australia, demonstrated the positive effects of mild hypothermia applied following cardiac arrest.[8] Responding to this research, in 2003 the American Heart Association (AHA) and the International Liaison Committee on Resuscitation (ILCOR) endorsed the use of targeted temperature management following cardiac arrest.[44] Currently, a growing percentage of hospitals around the world incorporate the AHA/ILCOR guidelines and include hypothermic therapies in their standard package of care for patients with cardiac arrest.[43] Some researchers go so far as to contend that hypothermia represents a better neuroprotectant following a blockage of blood to the brain than any known drug.[27] Over this same period a particularly successful research effort showed that hypothermia is a highly effective treatment when applied to newborn infants following birth asphyxia. Meta-analysis of a number of large randomised controlled trials showed that hypothermia for 72 hours started within 6 hours of birth significantly increased the chance of survival without brain damage.[45]

Research

edit

TTM has been studied in several use scenarios where it has not usually been found to be helpful, or is still under investigation, despite theoretical grounds for its usefulness.[46]

Stroke

edit

There is currently no evidence supporting targeted temperature management use in humans for stroke and clinical trials have not been completed.[47] Most of the data concerning hypothermia's effectiveness in treating stroke is limited to animal studies. These studies have focused primarily on ischemic stroke as opposed to hemorrhagic stroke, as hypothermia is associated with a lower clotting threshold. In these animal studies, hypothermia was represented an effective neuroprotectant.[48] The use of hypothermia to control intracranial pressure (ICP) after an ischemic stroke was found to be both safe and practical.[49]

Traumatic brain or spinal cord injury

edit

Animal studies have shown the benefit of targeted temperature management in traumatic central nervous system (CNS) injuries. Clinical trials have shown mixed results with regards to the optimal temperature and delay of cooling. Achieving therapeutic temperatures of 33 °C (91 °F) is thought to prevent secondary neurological injuries after severe CNS trauma.[50] A systematic review of randomised controlled trials in traumatic brain injury (TBI) suggests there is no evidence that hypothermia is beneficial.[51]

Cardiac arrest

edit

A clinical trial in cardiac arrest patients showed that hypothermia improved neurological outcome and reduced mortality.[8] A retrospective study of the use of hypothermia for cardiac arrest patients showed favorable neurological outcome and survival.[52] Osborn waves on electrocardiogram (ECG) are frequent during TTM after cardiac arrest, particularly in patients treated with 33 °C.[53] Osborn waves are not associated with increased risk of ventricular arrhythmia, and may be considered a benign physiological phenomenon, associated with lower mortality in univariable analyses.[53]

Neurosurgery

edit

As of 2015 hypothermia had shown no improvements in neurological outcomes or in mortality in neurosurgery.[54]

Naegleriasis

edit

TTM has been used in some cases of naegleriasis.[55]

See also

edit

References

edit
  1. ^ a b c Peberdy, MA; Callaway, CW; Neumar, RW; Geocadin, RG; Zimmerman, JL; Donnino, M; Gabrielli, A; Silvers, SM; Zaritsky, AL; Merchant, R; Vanden Hoek, TL; Kronick, SL; American Heart, Association (2 November 2010). "Part 9: post-cardiac arrest care: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care". Circulation. 122 (18 Suppl 3): S768–786. doi:10.1161/CIRCULATIONAHA.110.971002. PMID 20956225.
  2. ^ a b Bernard, Stephen A.; Gray, Timothy W.; Buist, Michael D.; Jones, Bruce M.; Silvester, William; Gutteridge, Geoff; Smith, Karen (21 February 2002). "Treatment of Comatose Survivors of Out-of-Hospital Cardiac Arrest with Induced Hypothermia". New England Journal of Medicine. 346 (8): 557–563. doi:10.1056/NEJMoa003289. PMID 11856794.
  3. ^ "Therapeutic Hypothermia After Cardiac Arrest". Johns Hopkins Medicine Health Library. Retrieved October 22, 2017.
  4. ^ a b Arrich, Jasmin; Schütz, Nikola; Oppenauer, Julia; Vendt, Janne; Holzer, Michael; Havel, Christof; Herkner, Harald (2023-05-22). "Hypothermia for neuroprotection in adults after cardiac arrest". The Cochrane Database of Systematic Reviews. 5 (5): CD004128. doi:10.1002/14651858.CD004128.pub5. ISSN 1469-493X. PMC 10202224. PMID 37217440.
  5. ^ Lewis, Sharon R.; Evans, David Jw; Butler, Andrew R.; Schofield-Robinson, Oliver J.; Alderson, Phil (September 21, 2017). "Hypothermia for traumatic brain injury". The Cochrane Database of Systematic Reviews. 2017 (9): CD001048. doi:10.1002/14651858.CD001048.pub5. ISSN 1469-493X. PMC 6483736. PMID 28933514.
  6. ^ Xiao, G.; Guo, Q.; Shu, M.; Xie, X.; Deng, J.; Zhu, Y.; Wan, C. (2012). "Safety profile and outcome of mild therapeutic hypothermia in patients following cardiac arrest: Systematic review and meta-analysis". Emergency Medicine Journal. 30 (2): 91–100. doi:10.1136/emermed-2012-201120. PMID 22660549. S2CID 23723711.
  7. ^ Ian Jacobs (Dec 17, 2013). "Targeted temperature management following cardiac arrest An update" (PDF). ilcor.org. Retrieved 14 November 2014.
  8. ^ a b c Holzer M, et al. (The Hypothermia after Cardiac Arrest Study Group) (21 February 2002). "Mild Therapeutic Hypothermia to Improve the Neurologic Outcome after Cardiac Arrest". New England Journal of Medicine. 346 (8): 549–556. doi:10.1056/NEJMoa012689. PMID 11856793.
  9. ^ Vargas, M; Servillo, G; Sutherasan, Y; Rodríguez-González, R; Brunetti, I; Pelosi, P (June 2015). "Effects of in-hospital low targeted temperature after out of hospital cardiac arrest: A systematic review with meta-analysis of randomized clinical trials". Resuscitation. 91: 8–18. doi:10.1016/j.resuscitation.2015.02.038. PMID 25796995.
  10. ^ Patel, JK; Parikh, PB (7 April 2016). "Association between therapeutic hypothermia and long-term quality of life in survivors of cardiac arrest: A systematic review". Resuscitation. 103: 54–59. doi:10.1016/j.resuscitation.2016.03.024. PMID 27060536.
  11. ^ Scholefield, BR; Silverstein, FS; Telford, R; Holubkov, R; Slomine, BS; Meert, KL; Christensen, JR; Nadkarni, VM; Dean, JM; Moler, FW (3 October 2018). "Therapeutic hypothermia after paediatric cardiac arrest: Pooled randomized controlled trials". Resuscitation. 133: 101–107. doi:10.1016/j.resuscitation.2018.09.011. PMC 6361524. PMID 30291883.
  12. ^ Arrich, Jasmin; Schütz, Nikola; Oppenauer, Julia; Vendt, Janne; Holzer, Michael; Havel, Christof; Herkner, Harald (22 May 2023). "Hypothermia for neuroprotection in adults after cardiac arrest". Cochrane Database of Systematic Reviews. 2023 (6): CD004128. doi:10.1002/14651858.CD004128.pub5. PMC 10202224. PMID 37217440.
  13. ^ Jacobs, SE; Berg, M; Hunt, R; Tarnow-Mordi, WO; Inder, TE; Davis, PG (31 January 2013). "Cooling for newborns with hypoxic ischaemic encephalopathy". The Cochrane Database of Systematic Reviews. 1 (1): CD003311. doi:10.1002/14651858.CD003311.pub3. PMC 7003568. PMID 23440789.
  14. ^ Gocoł, Radosław; Hudziak, Damian; Bis, Jarosław; Mendrala, Konrad; Morkisz, Łukasz; Podsiadło, Paweł; Kosiński, Sylweriusz; Piątek, Jacek; Darocha, Tomasz (January 2021). "The Role of Deep Hypothermia in Cardiac Surgery". International Journal of Environmental Research and Public Health. 18 (13): 7061. doi:10.3390/ijerph18137061. PMC 8297075. PMID 34280995.
  15. ^ Betts, J. Gordon (25 April 2013). "1.4 Requirements for Human Life". Anatomy and Physiology. Openstax. ISBN 978-1-947172-04-3. Retrieved 14 May 2023.
  16. ^ a b c d e Peberdy, MA; Callaway, CW; Neumar, RW; Geocadin, RG; Zimmerman, JL; Donnino, M; Gabrielli, A; Silvers, SM; Zaritsky, AL; Merchant, R; Vanden Hoek, TL; Kronick, SL; American Heart, Association (2 November 2010). "Part 9: post-cardiac arrest care: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care". Circulation. 122 (18 Suppl 3): S768–786. doi:10.1161/CIRCULATIONAHA.110.971002. PMID 20956225.
  17. ^ Geurts, Marjolein; MacLeod, Malcolm R.; Kollmar, Rainer; Kremer, Philip H. C.; Van Der Worp, H. Bart (2013). "Therapeutic Hypothermia and the Risk of Infection". Critical Care Medicine. 42 (2): 231–242. doi:10.1097/CCM.0b013e3182a276e8. PMID 23989182. S2CID 26412547.
  18. ^ Stockmann, H; Krannich, A; Schroeder, T; Storm, C (November 2014). "Therapeutic temperature management after cardiac arrest and the risk of bleeding: Systematic review and meta-analysis". Resuscitation. 85 (11): 1494–1503. doi:10.1016/j.resuscitation.2014.07.018. PMID 25132475.
  19. ^ Polderman KH, Peerdeman SM, Girbes AR (May 2001). "Hypophosphatemia and hypomagnesemia induced by cooling in patients with severe head injury". J Neurosurg. 94 (5): 697–705. doi:10.3171/jns.2001.94.5.0697. PMID 11354399. S2CID 25834720.
  20. ^ Kammersgaard, L.P.; Jørgensen, H.S.; Rungby, J.A.; Reith, J.; Nakayama, H.; Weber, U.J.; Houth, J.; Olsen, T.S. (2002). "Admission Body Temperature Predicts Long-Term Mortality After Acute Stroke: The Copenhagen Stroke Study". Stroke. 33 (7): 1759–1762. doi:10.1161/01.STR.0000019910.90280.F1. PMID 12105348.
  21. ^ a b c d e f g h i Polderman, Kees H. (2004). "Application of therapeutic hypothermia in the ICU: Opportunities and pitfalls of a promising treatment modality. Part 1: Indications and evidence". Intensive Care Medicine. 30 (4): 556–575. doi:10.1007/s00134-003-2152-x. PMID 14767591. S2CID 5733761.
  22. ^ Polderman, Kees H (2008). "Induced hypothermia and fever control for prevention and treatment of neurological injuries". The Lancet. 371 (9628): 1955–1969. doi:10.1016/S0140-6736(08)60837-5. PMID 18539227. S2CID 8691457.
  23. ^ Lau, Anthony; Tymianski, Michael (2010-07-01). "Glutamate receptors, neurotoxicity and neurodegeneration". Pflügers Archiv: European Journal of Physiology. 460 (2): 525–542. doi:10.1007/s00424-010-0809-1. PMID 20229265. S2CID 12421120.
  24. ^ a b c d e f Ferreira Da Silva, IR; Frontera, JA (November 2013). "Targeted temperature management in survivors of cardiac arrest". Cardiology Clinics. 31 (4): 637–655, ix. doi:10.1016/j.ccl.2013.07.010. PMID 24188226.
  25. ^ Taccone, FS; Donadello, K; Beumier, M; Scolletta, S (2011). "When, where and how to initiate hypothermia after adult cardiac arrest". Minerva Anestesiologica. 77 (9): 927–933. PMID 21878875.
  26. ^ a b Calver, P; Braungardt, T; Kupchik, N; Jensen, A; Cutler, C (2005). "The big chill: Improving the odds after cardiac arrest". RN. 68 (5): 58–62, quiz 63. PMID 15931934.
  27. ^ a b c Sessler, Daniel. "Thermoregulation and Heat Balance." Therapeutic Hypothermia. Ed. Mayer, Stephen and Sessler, Daniel. Marcel Decker: New York, 2005. 406
  28. ^ Choi, H. Alex; Ko, Sang-Bae; Presciutti, Mary; Fernandez, Luis; Carpenter, Amanda M.; Lesch, Christine; Gilmore, Emily; Malhotra, Rishi; Mayer, Stephan A. (2011-01-06). "Prevention of Shivering During Therapeutic Temperature Modulation: The Columbia Anti-Shivering Protocol". Neurocritical Care. 14 (3): 389–394. doi:10.1007/s12028-010-9474-7. ISSN 1541-6933. PMID 21210305. S2CID 21272649.
  29. ^ Diringer, Michael N.; Neurocritical Care Fever Reduction Trial Group (2004). "Treatment of fever in the neurologic intensive care unit with a catheter-based heat exchange system". Critical Care Medicine. 32 (2): 559–564. doi:10.1097/01.CCM.0000108868.97433.3F. PMID 14758179. S2CID 85796.
  30. ^ Hinz, Jos??; Rosmus, Martin; Popov, Aron; Moerer, Onnen; Frerichs, Inez; Quintel, Michael (2007). "Effectiveness of an Intravascular Cooling Method Compared with a Conventional Cooling Technique in Neurologic Patients". Journal of Neurosurgical Anesthesiology. 19 (2): 130–135. doi:10.1097/ANA.0b013e318032a208. PMID 17414000. S2CID 34579955.
  31. ^ Keller, E; Imhof, HG; Gasser, S; Terzic, A; Yonekawa, Y (2003). "Endovascular cooling with heat exchange catheters: A new method to induce and maintain hypothermia" (PDF). Intensive Care Medicine. 29 (6): 939–943. doi:10.1007/s00134-003-1685-3. PMID 12728304. S2CID 19971940.
  32. ^ Holzer, M.; Müllner, M.; Sterz, F.; Robak, O.; Kliegel, A.; Losert, H.; Sodeck, G.; Uray, T.; Zeiner, A.; Laggner, A. N. (2006). "Efficacy and Safety of Endovascular Cooling After Cardiac Arrest: Cohort Study and Bayesian Approach". Stroke. 37 (7): 1792–7. doi:10.1161/01.STR.0000227265.52763.16. PMID 16763179.
  33. ^ Pichon, Nicolas; Amiel, Jean; François, Bruno; Dugard, Anthony; Etchecopar, Caroline; Vignon, Philippe (2007). "Efficacy of and tolerance to mild induced hypothermia after out-of-hospital cardiac arrest using an endovascular cooling system". Critical Care. 11 (3): R71. doi:10.1186/cc5956. PMC 2206437. PMID 17598898.
  34. ^ Schwab, S.; Georgiadis, D.; Berrouschot, J.; Schellinger, P. D.; Graffagnino, C.; Mayer, S. A. (2001). "Feasibility and Safety of Moderate Hypothermia After Massive Hemispheric Infarction". Stroke. 32 (9): 2033–2035. doi:10.1161/hs0901.095394. PMID 11546893.
  35. ^ Haugk, Moritz; Sterz, Fritz; Grassberger, Martin; Uray, Thomas; Kliegel, Andreas; Janata, Andreas; Richling, Nina; Herkner, Harald; Laggner, Anton N. (2007). "Feasibility and efficacy of a new non-invasive surface cooling device in post-resuscitation intensive care medicine". Resuscitation. 75 (1): 76–81. doi:10.1016/j.resuscitation.2007.03.001. PMID 17462808.
  36. ^ Castren, M.; Nordberg, P.; Svensson, L.; Taccone, F.; Vincent, J.-L.; Desruelles, D.; Eichwede, F.; Mols, P.; Schwab, T.; Vergnion, M.; Storm, C.; Pesenti, A.; Pachl, J.; Guérisse, F.; Elste, T.; Roessler, M.; Fritz, H.; Durnez, P.; Busch, H.-J.; Inderbitzen, B.; Barbut, D. (2010). "Intra-Arrest Transnasal Evaporative Cooling: A Randomized, Prehospital, Multicenter Study (PRINCE: Pre-ROSC IntraNasal Cooling Effectiveness)". Circulation. 122 (7): 729–736. doi:10.1161/CIRCULATIONAHA.109.931691. PMID 20679548.
  37. ^ Busch, H.-J.; Eichwede, F.; Födisch, M.; Taccone, F.S.; Wöbker, G.; Schwab, T.; Hopf, H.-B.; Tonner, P.; Hachimi-Idrissi, S.; Martens, P.; Fritz, H.; Bode, Ch.; Vincent, J.-L.; Inderbitzen, B.; Barbut, D.; Sterz, F.; Janata, A. (2010). "Safety and feasibility of nasopharyngeal evaporative cooling in the emergency department setting in survivors of cardiac arrest" (PDF). Resuscitation. 81 (8): 943–949. doi:10.1016/j.resuscitation.2010.04.027. PMID 20627524.
  38. ^ Holden, M; Makic, MB (2006). "Clinically induced hypothermia: Why chill your patient?". AACN Advanced Critical Care. 17 (2): 125–132. doi:10.1097/00044067-200604000-00007. PMID 16767013. S2CID 32000169.
  39. ^ Clumpner, M; Mobley, J (2008). "Raising the dead. Prehospital hypothermia for cardiac arrest victims may improve neurological outcome and survival to discharge". EMS Magazine. 37 (9): 52–60. PMID 18839889.
  40. ^ Harris, B; Andrews, PJ; Murray, GD; Forbes, J; Moseley, O (2012). "Systematic review of head cooling in adults after traumatic brain injury and stroke". Health Technology Assessment. 16 (45): 1–175. doi:10.3310/hta16450. PMC 4781040. PMID 23171713.
  41. ^ Van Den Hurk, Corina J.; Peerbooms, Mijke; Van De Poll-Franse, Lonneke V.; Nortier, Johan W.; Coebergh, Jan Willem W.; Breed, Wim P. (2012). "Scalp cooling for hair preservation and associated characteristics in 1411 chemotherapy patients – Results of the Dutch Scalp Cooling Registry". Acta Oncologica. 51 (4): 497–504. doi:10.3109/0284186X.2012.658966. PMID 22304489. S2CID 26709009.
  42. ^ Jacobs, Susan E; Berg, Marie; Hunt, Rod; Tarnow-Mordi, William O; Inder, Terrie E; Davis, Peter G (31 January 2013). "Cooling for newborns with hypoxic ischaemic encephalopathy". Cochrane Database of Systematic Reviews. 2013 (1): CD003311. doi:10.1002/14651858.CD003311.pub3. PMC 7003568. PMID 23440789.
  43. ^ a b Ron Winslow (6 October 2009). "How Ice Can Save Your Life". Wall Street Journal. Retrieved 6 October 2009.
  44. ^ Nolan, J.P.; Morley, PT; Vanden Hoek, TL; Hickey, RW; Kloeck, WG; Billi, J; Böttiger, BW; Morley, PT; Nolan, JP; Okada, K; Reyes, C; Shuster, M; Steen, PA; Weil, MH; Wenzel, V; Hickey, RW; Carli, P; Vanden Hoek, TL; Atkins, D; International Liaison Committee on Resuscitation (2003). "Therapeutic Hypothermia After Cardiac Arrest: An Advisory Statement by the Advanced Life Support Task Force of the International Liaison Committee on Resuscitation". Circulation. 108 (1): 118–121. doi:10.1161/01.CIR.0000079019.02601.90. PMID 12847056.
  45. ^ Edwards, A D.; Brocklehurst, P.; Gunn, A. J; Halliday, H.; Juszczak, E.; Levene, M.; Strohm, B.; Thoresen, M.; Whitelaw, A.; Azzopardi, D. (2010). "Neurological outcomes at 18 months of age after moderate hypothermia for perinatal hypoxic ischaemic encephalopathy: Synthesis and meta-analysis of trial data". BMJ. 340: c363. doi:10.1136/bmj.c363. PMC 2819259. PMID 20144981.
  46. ^ Polderman KH (2009). "Mechanisms of action, physiological effects, and complications of hypothermia". Critical Care Medicine. 37 (7 Suppl): S186–202. doi:10.1097/CCM.0b013e3181aa5241. PMID 19535947. S2CID 6494903.
  47. ^ Targeted Temperature Management (Therapeutic Hypothermia) at eMedicine
  48. ^ Krieger, DW; De Georgia, MA; Abou-Chebl, A; Andrefsky, JC; Sila, CA; Katzan, IL; Mayberg, MR; Furlan, AJ (2001). "Cooling for acute ischemic brain damage (cool aid): An open pilot study of induced hypothermia in acute ischemic stroke". Stroke. 32 (8): 1847–1854. doi:10.1161/01.STR.32.8.1847. PMID 11486115.
  49. ^ Schwab, S.; Schwarz, S.; Spranger, M.; Keller, E.; Bertram, M.; Hacke, W. (1998). "Moderate Hypothermia in the Treatment of Patients with Severe Middle Cerebral Artery Infarction". Stroke. 29 (12): 2461–2466. doi:10.1161/01.STR.29.12.2461. PMID 9836751. INIST 1604537.
  50. ^ Arcure, Jess; Harrison, Eric E (Summer 2009). "Review Article of the Use of Early Hypothermia in the Treatment of Traumatic Brain Injuries" (PDF). Journal of Special Operations Medicine. 10 (3): 22–25. doi:10.55460/6EAQ-Z4AP. PMID 19739473. S2CID 12292935.
  51. ^ Lewis, Sharon R; Evans, David JW; Butler, Andrew R; Schofield-Robinson, Oliver J; Alderson, Phil (21 September 2017). "Hypothermia for traumatic brain injury". Cochrane Database of Systematic Reviews. 2017 (9): CD001048. doi:10.1002/14651858.CD001048.pub5. PMC 6483736. PMID 28933514.
  52. ^ Lundbye JB, Rai M, Kluger J (2012). "Therapeutic hypothermia is associated with improved neurologic outcome and survival in cardiac arrest survivors of non-shockable rhythms". Resuscitation. 83 (2): 202–207. doi:10.1016/j.resuscitation.2011.08.005. PMID 21864480.
  53. ^ a b Hadziselimovic, Edina; Thomsen, Jakob Hartvig; Kjaergaard, Jesper; Køber, Lars; Graff, Claus; Pehrson, Steen; Nielsen, Niklas; Erlinge, David; Frydland, Martin; Wiberg, Sebastian; Hassager, Christian (July 2018). "Osborn waves following out-of-hospital cardiac arrest—Effect of level of temperature management and risk of arrhythmia and death". Resuscitation. 128: 119–125. doi:10.1016/j.resuscitation.2018.04.037. ISSN 0300-9572. PMID 29723608. S2CID 19236851.
  54. ^ Galvin IM, Levy R, Boyd JG, Day AG, Wallace MC (2015). "Cooling for cerebral protection during brain surgery". Cochrane Database Syst Rev. 1 (1): CD006638. doi:10.1002/14651858.CD006638.pub3. PMC 10692402. PMID 25626888.
  55. ^ "Naegleria fowleri — Primary Amebic Meningoencephalitis (PAM) — Amebic Encephalitis". 23 April 2015. Archived from the original on 14 February 2015. Retrieved 17 January 2016.
edit

Sources

edit

  This article incorporates text from a free content work. Licensed under CC BY 4.0. Text taken from Anatomy and Physiology​, J. Gordon Betts et al, Openstax.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Targeted_temperature_management&oldid=1258610117"